OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
OKYO Pharma Limited is set to present its promising trial results for OK-101, a treatment for dry eye disease, at the International Tear Film & Ocular Surface Society Conference in Venice. The company is also advancing its Phase 2 trial for treating Neuropathic Corneal Pain, a market with no current FDA-approved therapies. These developments highlight OKYO’s commitment to addressing challenging ocular conditions and expanding its presence in the multi-billion-dollar eye care market.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue